Analytical Method Development
We have considerable experience in analytical method development using HPLC and LC-MS/MS and are expert in the bio-analysis of drugs.
We have studied a wide range of clinically available and novel small molecules including anti-metabolites, platinating and alkylating agents, peptides and anti-vascular compounds.
In collaboration with Professor Mark Hull at the University of Leeds, we have developed specific and highly sensitive methods for analysing specific prostaglandins and their metabolites using LC-MS/MS.
Methods are available for the analysis of, in particular tetranor- Prostaglandin E Metabolite (PGE-M), often used as a biomarker of PGE1 and PGE2 synthesis. We would be pleased to analyse urinary PGE-M levels for colleagues in academia and industry.
PGI-M and TX-M
We are currently developing similar methods for Prostaglandin I Metabolite (PGI-M) and Thromboxane metabolite (TX-M).
The use of LC-MS/MS allows rapid and sensitive analysis of clinical samples to a high standard, which can also be performed under GCLP conditions if required.
Method Development and Bioanalysis
Our analytical facilities include:
- A variety of HPLC kits
- Single quadrupole mass spectrometer (LC-MS)
- Two triple quadrupole mass spectrometers (LC-MS/MS)
- Capillary electrophoresis
- Nano HPLC
- MALDI mass spectrometry.
We have considerable experience in method development and drug analysis.
Prof Paul Loadman leads the team supported by technical staff with expertise in advanced research projects, clinical trials and providing support to industry.